AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes a portfolio of targeted medicines for oncology and other areas of unmet medical need. It markets its lead candidate, tivozanib, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC). The company has also completed a Phase 3 TIVO-3 trial of tivozanib for the treatment of advanced RCC; and initiated enrollment in a phase Ib/II clinical trial of tivozanib in combination with Opdivo (nivolumab), an immune checkpoint (PD-1) inhibitor, for the treatment of advanced RCC. In addition, it is developing Ficlatuzumab, a potent hepatocyte growth factor inhibitory antibody, in Phase I and Phase II clinical trials in squamous cell carcinoma of the head and neck, metastatic pancreatic ductal cancer, and acute myeloid leukemia; and AV-203, a potent anti-ErbB3 specific monoclonal antibody, which has completed Phase I clinical trial for treating esophageal cancer. The company's preclinical stage products include AV-380, a potent humanized IgG1 inhibitory monoclonal antibody for the treatment or prevention of cachexia; and AV-353 for the treatment of pulmonary arterial hypertension. It has strategic partnerships with CANbridge Life Sciences Ltd.; EUSA Pharma (UK) Limited; Novartis International Pharmaceutical Ltd.; Biodesix, Inc.; St. Vincent's Hospital Sydney Limited; Biogen Idec; and Kyowa Hakko Kirin Co., Ltd. AVEO Pharmaceuticals, Inc. has a clinical collaboration with AstraZeneca PLC to evaluate IMFINZI (durvalumab), a human monoclonal antibody directed against programmed death-ligand 1 (PD-L1). The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is based in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryBiotechnology
SectorMedical
Phone617-588-1960
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$7.58 million
Profitability
Miscellaneous
Employees19
Next Earnings Date5/14/2019 (Estimated)
OptionableOptionable
AVEO Pharmaceuticals (NASDAQ:AVEO) Frequently Asked Questions
What is AVEO Pharmaceuticals' stock symbol?
AVEO Pharmaceuticals trades on the NASDAQ under the ticker symbol "AVEO."
How were AVEO Pharmaceuticals' earnings last quarter?
AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) released its earnings results on Tuesday, May, 8th. The biopharmaceutical company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.07) by $0.00. The biopharmaceutical company had revenue of $1.03 million for the quarter, compared to analysts' expectations of $0.98 million. View AVEO Pharmaceuticals' Earnings History.
When is AVEO Pharmaceuticals' next earnings date?
What price target have analysts set for AVEO?
6 equities research analysts have issued 1-year price objectives for AVEO Pharmaceuticals' stock. Their predictions range from $1.00 to $3.00. On average, they anticipate AVEO Pharmaceuticals' stock price to reach $2.20 in the next twelve months. This suggests a possible upside of 260.7% from the stock's current price. View Analyst Price Targets for AVEO Pharmaceuticals.
What is the consensus analysts' recommendation for AVEO Pharmaceuticals?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AVEO Pharmaceuticals in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for AVEO Pharmaceuticals.
What are Wall Street analysts saying about AVEO Pharmaceuticals stock?
Here are some recent quotes from research analysts about AVEO Pharmaceuticals stock:
- 1. HC Wainwright analysts commented, "We maintain our Neutral rating on AVEO and our 12-month price target of $1.00 per share. We derive our price target based on a risk-adjusted NPV analysis of projected tivozanib and ficlatuzumab revenues through 2030 assuming a 12.0% discount rate and a 0% terminal growth rate. We derive an rNPV of $231M for the products and add in pro forma net cash and cash equivalents of $12.9M to arrive at a 12-month price target of $1.01 per diluted share, which we round to $1.00. (1) clinical; (2) commercial; (3) financial; (4) partnership; and (5) intellectual property." (3/18/2019)
- 2. According to Zacks Investment Research, "AVEO got a huge boost with the approval of Fotivda in Europe for first-line treatment of advanced renal cell carcinoma. AVEO is progressing well with its TIVO-3 study intended for an FDA nod in the United States. However, the company has extended the review timeline from the third to the fourth quarter of 2018 for top-line data from the phase III TIVO-3 study. Although, the targeted market is lucrative, dependence on partners for pipeline development as well as funds is a concern. Failure to receive regulatory approvals or the termination of a deal would hamper AVEO’s future prospects. AVEO suffered a string of pipeline setbacks in the past, which might leave an adverse impact on the stock. Moreover, shares of the company have underperformed the industry so far this year. Loss estimates have narrowed ahead of the company’s Q3 earnings release. The company has a dismal record of earnings surprises in recent quarters." (11/12/2018)
Has AVEO Pharmaceuticals been receiving favorable news coverage?
News stories about AVEO stock have been trending very negative recently, according to InfoTrie Sentiment. The research group scores the sentiment of news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. AVEO Pharmaceuticals earned a news sentiment score of -3.4 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the next few days.
Are investors shorting AVEO Pharmaceuticals?
AVEO Pharmaceuticals saw a increase in short interest in February. As of February 15th, there was short interest totalling 17,037,577 shares, an increase of 13.1% from the January 31st total of 15,065,912 shares. Based on an average trading volume of 6,293,870 shares, the days-to-cover ratio is presently 2.7 days. Currently, 17.0% of the shares of the company are sold short. View AVEO Pharmaceuticals' Current Options Chain.
Who are some of AVEO Pharmaceuticals' key competitors?
Some companies that are related to AVEO Pharmaceuticals include Harpoon Therapeutics (HARP), AC Immune (ACIU), Syros Pharmaceuticals (SYRS), Cellular Biomedicine Group (CBMG), Merus (MRUS), Akumin (AKU), Karyopharm Therapeutics (KPTI), Evelo Biosciences (EVLO), Benchmark (BMK), Kala Pharmaceuticals (KALA), Iradimed (IRMD), Immune Design (IMDZ), Savara (SVRA), Medical Developments (MVP) and Clover (CLV).
What other stocks do shareholders of AVEO Pharmaceuticals own?
Who are AVEO Pharmaceuticals' key executives?
AVEO Pharmaceuticals' management team includes the folowing people:
- Mr. Michael P. Bailey, CEO, Pres & Director (Age 54)
- Mr. Matthew D. Dallas, Chief Financial Officer (Age 44)
- Dr. Michael N. Needle, Chief Medical Officer (Age 59)
- Dr. Nikhil Mehta Ph.D., Sr. VP of Regulatory & Quality Assurance (Age 60)
- Dr. Emile Farhan Ph.D., VP of Technical Operations
Who are AVEO Pharmaceuticals' major shareholders?
AVEO Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include NEA Management Company LLC (16.67%), BlackRock Inc. (5.87%), 683 Capital Management LLC (1.50%), Geode Capital Management LLC (1.11%), Geode Capital Management LLC (1.11%) and Northern Trust Corp (0.94%). Company insiders that own AVEO Pharmaceuticals stock include Anthony B Evnin, Equity Opportunities Iv Growth, Peter J Barris, Peter W Sonsini and Ravi Viswanathan. View Institutional Ownership Trends for AVEO Pharmaceuticals.
Which institutional investors are selling AVEO Pharmaceuticals stock?
Which institutional investors are buying AVEO Pharmaceuticals stock?
AVEO stock was purchased by a variety of institutional investors in the last quarter, including NEA Management Company LLC, Geode Capital Management LLC, Geode Capital Management LLC, D. E. Shaw & Co. Inc., BlackRock Inc., New York State Common Retirement Fund, Bank of New York Mellon Corp and Hikari Power Ltd. Company insiders that have bought AVEO Pharmaceuticals stock in the last two years include Anthony B Evnin, Equity Opportunities Iv Growth, Peter J Barris, Peter W Sonsini and Ravi Viswanathan. View Insider Buying and Selling for AVEO Pharmaceuticals.
How do I buy shares of AVEO Pharmaceuticals?
Shares of AVEO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is AVEO Pharmaceuticals' stock price today?
One share of AVEO stock can currently be purchased for approximately $0.61.
How big of a company is AVEO Pharmaceuticals?
AVEO Pharmaceuticals has a market capitalization of $76.46 million and generates $7.58 million in revenue each year. The biopharmaceutical company earns $-65,020,000.00 in net income (profit) each year or ($0.16) on an earnings per share basis. AVEO Pharmaceuticals employs 19 workers across the globe.
What is AVEO Pharmaceuticals' official website?
How can I contact AVEO Pharmaceuticals?
AVEO Pharmaceuticals' mailing address is ONE BROADWAY 14TH FLOOR, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-588-1960 or via email at [email protected]
MarketBeat Community Rating for AVEO Pharmaceuticals (NASDAQ AVEO)
MarketBeat's community ratings are surveys of what our community members think about AVEO Pharmaceuticals and other stocks. Vote "Outperform" if you believe AVEO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AVEO will underperform the S&P 500 over the long term. You may vote once every thirty days.
